NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$16.39 USD
-0.61 (-3.59%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $16.33 -0.06 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NAMS 16.39 -0.61(-3.59%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAMS
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and uniQure (QURE)
NewAmsterdam Pharma Company (NAMS) Gets a Buy from Scotiabank
RBC Capital Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Strong Buy Rating for NewAmsterdam Pharma Backed by Obicetrapib’s Efficacy and Market Potential
NewAmsterdam Pharma GAAP EPS of -$0.41, revenue of $2.27M